Check out our hot-just-out-of-the-press paper Shadbahr et al. PI-RADS v2 and Adverse Prostate Cancer Outcomes in @EurUrolOncol : https://t.co/hnzkj3etoh
Early adopters in MRI systematic scoring coming together to combine MRI and biopsies in #prostatecancer#diagnostics#prognosis
We have a fully funded 3 year PhD post @ucl starting Aug 2025. Research is on optimising prostate cancer diagnosis using imaging (e.g MRI, PET, AI). Join our world-class team with proven track-record for changing practice. DM me if interested @BURSTurology@BSUroRad@ESRUrology
Compared to Goteborg 2 screening (PSA then MRI; NEJM) and PROSCREEN (PSA then marker then MRI; JAMA), BARCODE PRS based screening found fewer significant cancers (grade group 2+), more insignificant cancer and biopsied more men (the trifecta!). https://t.co/9x3nVIcwA1
Submit an abstract by April 16 for the AACR Special Conference on Artificial Intelligence and Machine Learning (July 10-12; Montreal), chaired by Valentina Boeva, @MarzyehGhassemi, Benjamin Haibe-Kains, and @BoWang87:
https://t.co/HoDltJdRd8
#AACRai25@val_boeva@bhaibeka
1/ 🚨New preprint out on medRxiv
We found that PI-RADS v2 score 5 is a powerful predictor of prostate cancer-specific mortality (PCSM).
MRI is not just diagnostic—it's prognostic.
📰https://t.co/5iC3dOZGT9
#ProstateCancer#MRI @TolouShadbahr
We are thrilled to welcome Dr. Denis Rustand, a postdoctoral fellow at @bayescomp_inla @cemseKAUST, who will visit our group next month!🎉
Besides strengthening our research collaboration, Denis will deliver an exciting talk on #INLAjoint (1/2) #DataScience#INLA#JointModels
Tomorrow I'll be discussing cancer research and the Pink Ribbon campaign on @huomentasuomi (10 AM, MTV3). Later in the evening, our lab will be featured on a special charity episode of Dancing with the Stars! Hoping for a big win for Finnish cancer research- patients deserve it🌸
I am glad to have participated in the #FCIsymposium2024, excellent speakers and insightful talks. I was particularly interested in #AI for #DigitalPathology and the advances in the field. Thank you @CancerInstFIN for organizing this event and @Kuopionkaupunki for the warm welcome
One week to go! Preparations for the greatest #cancerresearch event in Finland this year are at full steam. We are expecting over 250 participants and 70 posters in addition to our magnificent lineup for speakers. C U next week! @CancerInstFIN@UEFcancer#syöpätutkimus@ficaneast
One week to go! Preparations for the greatest #cancerresearch event in Finland this year are at full steam. We are expecting over 250 participants and 70 posters in addition to our magnificent lineup for speakers. C U next week! @CancerInstFIN@UEFcancer#syöpätutkimus@ficaneast
Also what’s made in universities is made by people. Proud of all my peers and students, all who make efforts towards our common goals @HelsinkiUniMed@helsinkiuni@HUS_fi
Kiitos lahjoittajien, Syöpäsäätiö on voinut tukea pitkäjänteisesti miesten yleisten syöpien kuten eturauhassyövän tutkimusta Suomessa. ProScreen-tutkimuksessa on saatu uusia, lupaavia tuloksia. Lue lisää: https://t.co/3GiLhkujk4 #eturauhassyöpä#miestensyövät#syöpätutkimus
We take also seriously the inter-pathologists variation amongst our screening sites. Expected impact of MRI-targeted biopsy interreader variability among uropathologists on ProScreen prostate cancer s… https://t.co/b4bsFxE9g9
Worried about systematic biopsies being omitted in ProScreen trial?
We’ve digged deep into the nMRI lesions and believe that rescreening and PSA-D trigger are proper safety tailgates👇
https://t.co/zoD5784fgY
Seems we’re on a right path towards proper benefit to harm ratio in PCa screening with this 3-tiered algorithm. Importantly, we’re powered for PCa mortality outcome!